Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters

Database
Language
Journal subject
Publication year range
3.
J Dermatol Sci ; 104(1): 30-38, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34479772

ABSTRACT

BACKGROUND: Organ transplant recipients show a high incidence for the formation of cutaneous squamous cell carcinoma (cSCC), while sirolimus appears to reduce the risk. GRO-α is a chemokine, which is overexpressed in many tumor entities and associated with malignant transformation. However, little is known about the expression and function of GRO-α in human cSCC. OBJECTIVE: Our aim was to investigate the relevance of the GRO-α (CXCL-1)/ CXCR2 axis in human cSCC and the potential impact of sirolimus. METHODS: We analyzed the GRO-α expression in human keratinocytes, different cSCC cell lines as well as cSCC tissue and investigated its effect on cell proliferation and migration. Additionally, we incubated cells with sirolimus and measured the expression of GRO-α and its receptor CXCR2. RESULTS: We showed that both constitutive as well as induced GRO-α expression is higher in in cSCC cell lines compared to keratinocytes and that GRO-α protein is detectable in human cSCC tissue. By GRO-α exposure and shRNA knock down, we identified GRO-α as a driving factor in proliferation and migration. Moreover, in a dermis equivalent GRO-α knocked down cSCC cell lines displayed a reduced capacity in tumor nest formation. Incubation with sirolimus significantly inhibited GRO-α expression in keratinocytes as well as tumor cell lines. Moreover, sirolimus decreased the expression of the corresponding receptor CXCR2. CONCLUSION: Taken together, our results suggest that the GRO-α/CXCR2 axis plays a role in human keratinocyte carcinogenesis and might represent a molecular mechanism for the preventive effect of mTOR inhibitors in cSCC development.


Subject(s)
Carcinoma, Squamous Cell/prevention & control , Chemokine CXCL1/metabolism , MTOR Inhibitors/pharmacology , Receptors, Interleukin-8B/metabolism , Skin Neoplasms/prevention & control , Carcinogenesis/drug effects , Carcinogenesis/immunology , Carcinoma, Squamous Cell/immunology , Carcinoma, Squamous Cell/pathology , Cell Line, Tumor , Chemokine CXCL1/antagonists & inhibitors , Chemokine CXCL1/genetics , Gene Knockdown Techniques , Humans , Keratinocytes/drug effects , Keratinocytes/immunology , Keratinocytes/metabolism , MTOR Inhibitors/therapeutic use , Receptors, Interleukin-8B/antagonists & inhibitors , Signal Transduction/drug effects , Signal Transduction/immunology , Sirolimus/pharmacology , Sirolimus/therapeutic use , Skin Neoplasms/immunology , Skin Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL